The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Feb. 21, 2018
Applicant:

Emory University, Atlanta, GA (US);

Inventors:

Dennis Liotta, Atlanta, GA (US);

Edgars Jecs, Decatur, GA (US);

Robert James Wilson, Gansevoort, NY (US);

Huy Hoang Nguyen, Norcross, GA (US);

Michelle Bora Kim, Chamblee, GA (US);

Lawrence Wilson, Atlanta, GA (US);

Eric James Miller, Atlanta, GA (US);

Yesim Altas Tahirovic, Atlanta, GA (US);

Valarie Truax, North Haven, CT (US);

Assignee:

Emory University, Atlanta, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 487/08 (2006.01); A61K 31/4725 (2006.01); A61P 35/00 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/4995 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/4995 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61P 35/00 (2018.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01);
Abstract

The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.


Find Patent Forward Citations

Loading…